New Zealand Continuous Glucose Monitoring Devices Market Size (2024 - 2029)

New Zealand Continuous Glucose Monitoring Devices Market Analysis

The New Zealand Continuous Glucose Monitoring Devices Market size is estimated at USD 50.91 million in 2024, and is expected to reach USD 91.07 million by 2029, growing at a CAGR of 13.60% during the forecast period (2024-2029).

The COVID-19 pandemic highlighted that substantially greater attention had to be given to diabetes to avoid unnecessary and inequitable outcomes from the infection. All necessary steps were taken and maintained to protect this high-risk group through nationwide public health measures to prevent transmission, ensuring vaccination has been given and undertaking workplace risk assessments. Notably, the rates of diabetes are higher among Maori, Pacific, and South Asians compared with New Zealand Europeans, particularly those living in deprived situations. These groups were especially vulnerable to the far-reaching impacts of the COVID-19 crisis, as they were disproportionately exposed to risk, potentially exacerbated by the sudden loss of jobs and income and reduced access to usual social support and healthcare. 

Mediray (Distributor Company for Freestyle Libre Products) was classed as an essential service and continued to provide FreeStyle Libre systems as usual. The Mediray technical support line remained open for call-in and pick-up options. Such factors impacted market growth positively during the pandemic.

In 2021, the Ministry of Health Virtual Diabetes Register estimated that more than 290,000 people were living with diabetes. The Pacific population had the highest estimated rate of diabetes, followed by the Indian population and the Māori population in New Zealand. The European or other populations had the lowest estimated rate of diabetes. Blood glucose level testing is a crucial technology for Diabetes because it facilitates knowledge of how different foods, medications, and activities affect a patient's diabetes and how much insulin is needed, and when for effective diabetes management. Generally, glucose testing was done with finger-pricking kits that measure levels via small blood samples. Currently, automated glucose monitoring systems are being used.

Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device worn on the body (typically the abdomen or arm) and held on by an adhesive patch. The sensor part of the device has a cannula that is inserted into the top layer of skin and uses samples of interstitial fluid to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. The usage of CGMs for people with Diabetes and their caregivers and communities is beneficial for managing their blood glucose and insulin levels to maintain their health outcomes. 

CGM makes it significantly easier to manage blood glucose levels by decreasing interruptions, allowing for better sleep and improving the mental health of patients or caregivers by reducing the overall mental load of managing diabetes, thereby enhancing the market prospects in the years to come.

New Zealand Continuous Glucose Monitoring Devices Industry Segmentation

CGM, as a wearable sensor, automatically detects and measures blood glucose levels around the clock. Data is then sent from the sensor to a receiver or smart device using a transmitter that is placed above the skin. Patients receive alerts from the transmitter or monitor their current glucose level and trends wirelessly, and it notifies patients when it’s time to replace the sensor. The New Zealand Continuous Glucose Monitoring Devices Market is segmented into Components (Sensors and Durables) and by Provinces. The report offers the value (in USD) and volume (in Units) for the above segments.